Alto Neuroscience (ANRO) Competitors $3.64 +0.14 (+3.85%) Closing price 03:59 PM EasternExtended Trading$3.67 +0.02 (+0.69%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. KMDA, AURA, YMAB, VIGL, AQST, OLMA, RCKT, FULC, ABEO, and ALDXShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Kamada (KMDA), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors Kamada Aura Biosciences Y-mAbs Therapeutics Vigil Neuroscience Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Aldeyra Therapeutics Alto Neuroscience (NYSE:ANRO) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Do institutionals and insiders have more ownership in ANRO or KMDA? 20.4% of Kamada shares are owned by institutional investors. 11.1% of Alto Neuroscience shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer ANRO or KMDA? In the previous week, Alto Neuroscience had 21 more articles in the media than Kamada. MarketBeat recorded 26 mentions for Alto Neuroscience and 5 mentions for Kamada. Kamada's average media sentiment score of 0.61 beat Alto Neuroscience's score of 0.12 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 22 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Kamada 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ANRO or KMDA? Kamada has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.39-1.53Kamada$160.95M2.55$14.46M$0.3421.00 Do analysts recommend ANRO or KMDA? Alto Neuroscience currently has a consensus target price of $8.50, indicating a potential upside of 133.20%. Kamada has a consensus target price of $13.00, indicating a potential upside of 82.07%. Given Alto Neuroscience's higher probable upside, equities research analysts clearly believe Alto Neuroscience is more favorable than Kamada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is ANRO or KMDA more profitable? Kamada has a net margin of 11.22% compared to Alto Neuroscience's net margin of 0.00%. Kamada's return on equity of 7.41% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -44.34% -36.73% Kamada 11.22%7.41%5.18% Which has more risk and volatility, ANRO or KMDA? Alto Neuroscience has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Kamada has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. SummaryKamada beats Alto Neuroscience on 11 of the 15 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$98.71M$3.16B$5.77B$21.32BDividend YieldN/A2.28%6.67%3.52%P/E Ratio-1.5321.1075.6029.64Price / SalesN/A467.69555.1849.98Price / CashN/A45.1137.1124.13Price / Book0.659.8611.444.55Net Income-$61.43M-$53.47M$3.28B$999.70M7 Day Performance-1.62%2.89%0.84%0.55%1 Month Performance18.34%8.62%7.15%5.67%1 Year Performance-71.34%13.69%59.65%15.62% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience2.8538 of 5 stars$3.65+3.8%$8.50+133.2%-73.7%$98.71MN/A-1.53N/AKMDAKamada4.3776 of 5 stars$6.92-1.4%$13.00+87.9%+29.3%$397.93M$160.95M20.35360Positive NewsShort Interest ↑AURAAura Biosciences2.5852 of 5 stars$6.26-2.6%$22.00+251.4%-16.5%$388.87MN/A-3.1950Positive NewsYMABY-mAbs Therapeutics3.0257 of 5 stars$8.55+0.1%$9.62+12.5%-40.3%$388.50M$87.68M-17.10150Positive NewsShort Interest ↓VIGLVigil Neuroscience1.4776 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340AQSTAquestive Therapeutics2.1379 of 5 stars$3.77-1.6%$10.14+169.0%+19.3%$375.96M$57.56M-5.39160Trending NewsAnalyst UpgradeAnalyst RevisionOLMAOlema Pharmaceuticals2.7097 of 5 stars$5.46-1.1%$24.00+339.6%-44.5%$374.74MN/A-2.7670News CoverageAnalyst ForecastAnalyst RevisionRCKTRocket Pharmaceuticals4.9033 of 5 stars$3.28-2.1%$16.73+410.2%-81.9%$353.92MN/A-1.31240Positive NewsFULCFulcrum Therapeutics0.4966 of 5 stars$6.48-2.6%$7.57+16.8%-16.6%$350.51M$80M-5.31100News CoveragePositive NewsABEOAbeona Therapeutics4.2995 of 5 stars$6.83-0.7%$19.50+185.5%+23.2%$350.23M$3.50M9.7690ALDXAldeyra Therapeutics2.4895 of 5 stars$5.84-0.3%$9.50+62.7%-12.5%$349.79MN/A-6.8710Positive News Related Companies and Tools Related Companies Kamada Competitors Aura Biosciences Competitors Y-mAbs Therapeutics Competitors Vigil Neuroscience Competitors Aquestive Therapeutics Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Fulcrum Therapeutics Competitors Abeona Therapeutics Competitors Aldeyra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
